CTOs on the Move

Access Integrated Healthcare

www.accessih.com

 
Founded by Chief Executive Officer Sam Solakyan, Global Holdings, Inc. has excelled in its journey in becoming leaders in each of the industries it has a presence in. Their main responsibility lies in providing their clients with the most premiere level of service. More than just your typical holdings group, Global is a multifaceted company with financial assets and ownership in the radiology, pharmaceuticals, and medical billing and collections industries. Instead of merely buying and selling companies like other holdings groups, Global searches for the less desirable companies with hidden potential and applies its knowledge and expertise in the management ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.accessih.com
  • 550 N. Brand Blvd. 20th Floor
    Glendale, CA USA 91203
  • Phone: 866.460.7465

Executives

Name Title Contact Details

Similar Companies

Plexus Learning Designs

Plexus Learning Designs is a Marblehead, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MEDWRITE Medical Communications

MEDWRITE Medical Communications is a Maiden Rock, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StausOne Health Systems

StausOne Health Systems is a Westborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orthomerica

We are a developer, manufacturer and marketer of prefabricated, semi-custom and custom orthoses. Orthomerica is known for providing exceptional customer service, quality, innovation and prompt delivery of orthopaedic braces to the orthotics and

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.